Chronic urticaria (CU) is frequently managed with Omalizumab in cases where antihistamines are ineffective, but little research has focused on its use in Latin America, particularly in Colombia.
A study was conducted with 123 patients in Colombia from 2014 to 2017, primarily consisting of women (73.1%) with an average age of 47.1 years, where most patients were diagnosed with chronic spontaneous urticaria.
Emotional factors such as anxiety and stress were significant among patients, with 34.9% reporting anxiety symptoms and 34.1% experiencing exacerbations due to stress, highlighting the psychological aspect of CU management.